Substantial or complete myocardial recovery occurs in many patients with heart failure (HF). HF patients with myocardial recovery or recovered left ventricular (LV) ejection fraction (EF; HFrecEF) are a distinct population of HF patients with different underlying etiologies, comorbidities, response to therapies, and outcomes compared with HF patients with persistent reduced or preserved EF. Improvement in LVEF has been systematically linked to improved quality of life, and lower rehospitalization rates and mortality. However, the mortality and morbidity in HFrecEF patients remain higher than those in the normal population. Currently, data to guide the management of HFrecEF patients are lacking. This review discusses specific characteristics, pathophysiology, and clinical implications for HFrecEF.
Left ventricle Ejection fraction Heart failure Echocardiography
This is a preview of subscription content, log in to check access.
Compliance with ethical standards
Conflict of interest
Kazuaki Tanabe and Takahiro Sakamoto declare that they have no conflicts of interest.
All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1964 and later revisions.
Informed consent was obtained from all patients for being included in this review.
Yancy C, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2013;128:e240–327.CrossRefGoogle Scholar
Punnoose L, Givertz M, Lewis E, et al. Heart failure with recovered ejection fraction: a distinct clinical entity. J Card Fail. 2011;17:527–32.CrossRefPubMedCentralGoogle Scholar
Basuray A, French B, Ky B, et al. Heart failure with recovered ejection fraction: clinical description, biomarkers and outcomes. Circulation. 2014;129:2380–7.CrossRefPubMedCentralGoogle Scholar
Ponikowski P, Voors A, Anker S, et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Eur Heart J. 2016;37:2129–200.CrossRefPubMedCentralGoogle Scholar
Dunlay SM, Roger VL, Weston SA, et al. Longitudinal changes in ejection fraction in heart failure patients with preserved and reduced ejection fraction. Circ Heart Fail. 2012;5:720–6.CrossRefPubMedCentralGoogle Scholar
Packer M, Antonopoulos GV, Berlin JA, et al. Comparative effects of carvedilol and metoprolol on left ventricular ejection fraction in heart failure: results of a meta-analysis. Am Heart J. 2001;141:899–907.CrossRefPubMedCentralGoogle Scholar
van Campen LC, Visser FC, Visser CA. Ejection fraction improvement by beta-blocker treatment in patients with heart failure: an analysis of studies published in the literature. J Cardiovasc Pharmacol. 1998;32(Suppl 1):S31–5.PubMedPubMedCentralGoogle Scholar
Wake M, Yoshitomi H, Ito S, et al. Long-term echocardiographic follow-up of a patient with peripartum cardiomyopathy. J Cardiol Jpn Ed. 2012;7:91–5.Google Scholar
Kawahara H, Takahashi N, Yoshitomi H, et al. A breast cancer patient with chemotherapy-induced cardiomyopathy that was reversible with medical therapy. Shinzo. 2014;46:521–7.Google Scholar
D’Ambrosio A, Patti G, Manzoli A, et al. The fate of acute myocarditis between spontaneous improvement and evolution to dilated cardiomyopathy: a review. Heart. 2001;85:499–504.CrossRefPubMedCentralGoogle Scholar
Kramer DG, Trikalinos TA, Kent DM, et al. Quantitative evaluation of drug or device effects on ventricular remodeling as predictors of therapeutic effects on mortality in patients with heart failure and reduced ejection fraction: a meta-analytic approach. J Am Coll Cardiol. 2010;56:392–406.CrossRefPubMedCentralGoogle Scholar
McNamara DM, Eikayam U, Alharethi R, et al. Clinical outcomes for peripartum cardiomyopathy in North America: results of the IPAC study (investigations of pregnancy-associated cardiomyopathy). J Am Coll Cardiol. 2015;66:905–14.CrossRefPubMedCentralGoogle Scholar
Wilcox JE, Fonarow GC, Yancy CW, et al. Factors associated with improvement in ejection fraction in clinical practice among patients with heart failure: findings from IMPROVE HF. Am Heart J. 2012;163:49–56.CrossRefPubMedCentralGoogle Scholar
Konstam MA. Reliability of ventricular remodeling as a surrogate for use in conjunction with clinical outcomes in heart failure. Am J Cardiol. 2005;96:867–71.CrossRefPubMedCentralGoogle Scholar
Kubanek M, Sramko M, Maluskova J, et al. Novel predictors of left ventricular reverse remodeling in individuals with recent-onset dilated cardiomyopathy. J Am Coll Cardiol. 2013;61:54–63.CrossRefPubMedCentralGoogle Scholar
Sjoblom J, Muhrbeck J, Witt N, et al. Evolution of left ventricular ejection fraction after acute myocardial infarction: implications for implantable cardioverter-defibrillator eligibility. Circulation. 2014;130:743–8.CrossRefPubMedCentralGoogle Scholar
Camici PG, Prasad SK, Rimoldi OE. Stunning, hibernation, and assessment of myocardial viability. Circulation. 2008;117:103–14.CrossRefGoogle Scholar
Giannuzzi P, Temporelli PL, Bosimini E, et al. Heterogeneity of left ventricular remodeling after acute myocardial infarction: results of the Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto Miocardico-3 Echo Substudy. Am Heart J. 2001;141:131–8.CrossRefPubMedCentralGoogle Scholar
Chaudhry FA, Tauke JT, Alessandrini RS, et al. Prognostic implications of myocardial contractile reserve in patients with coronary artery disease and left ventricular dysfunction. J Am Coll Cardiol. 1999;34:730–8.CrossRefPubMedCentralGoogle Scholar
Lupon J, Gavidia-Bovadilla G, Ferrer E, et al. Dynamic trajectories of left ventricular ejection fraction in heart failure. J Am Coll Cardiol. 2018;72:591–601.CrossRefPubMedCentralGoogle Scholar
MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: metoprolol CR/XL Randomised Intervention Trial in-Congestive Heart Failure (MERIT-HF). Lancet. 1999;353:2001–7.CrossRefGoogle Scholar
Greenberg B, Quinones MA, Koilpillai C, et al. Effects of long-term enalapril therapy on cardiac structure and function in patients with left ventricular dysfunction. Results of the SOLVD echocardiography substudy. Circulation. 1999;91:2573–81.CrossRefGoogle Scholar
Wong M, Staszewsky L, Latini R, et al. Valsartan benefits left ventricular structure and function in heart failure: val-HeFT echocardiographic study. J Am Coll Cardiol. 2002;40:970–5.CrossRefPubMedCentralGoogle Scholar
Tsutamoto T, Wada A, Maeda K, et al. Effect of spironolactone on plasma brain natriuretic peptide and left ventricular remodeling in patients with congestive heart failure. J Am Coll Cardiol. 2001;37:1228–33.CrossRefGoogle Scholar
Ukkonen H, Beanlands RS, Burwash IG, et al. Effect of cardiac resynchronization on myocardial efficiency and regional oxidative metabolism. Circulation. 2003;107:28–31.CrossRefPubMedCentralGoogle Scholar
Hamdan MH, Zagrodzky JD, Joglar JA, et al. Biventricular pacing decreases sympathetic activity compared with right ventricular pacing in patients with depressed ejection fraction. Circulation. 2000;102:1027–32.CrossRefPubMedCentralGoogle Scholar
Basulay A, Fang JC. Management of patients with recovered systolic function. Prog Cardiovasc Dis. 2016;56:434–43.CrossRefGoogle Scholar